Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

LCCC 1210 - Phase II, Multicenter, Single Arm Study of the Tolerability of Weekly Nab-paclitaxel as Second Line Treatment for Elderly Patients With Advanced Lung Cancer

Authors not listed

UNC Lineberger Comprehensive Cancer Center · 2013

Abstract

The purpose of this study is to evaluate the safety and efficacy of weekly nab-paclitaxel for a second-line treatment in elderly subjects, 70 years of age or greater, with non-small cell lung cancer (NSCLC)

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-01 MST

Cite this

APA
Anonymous. (2013). LCCC 1210 - Phase II, Multicenter, Single Arm Study of the Tolerability of Weekly Nab-paclitaxel as Second Line Treatment for Elderly Patients With Advanced Lung Cancer. <em>UNC Lineberger Comprehensive Cancer Center</em>. https://clinicaltrials.gov/study/NCT01702844
Vancouver
Anonymous. LCCC 1210 - Phase II, Multicenter, Single Arm Study of the Tolerability of Weekly Nab-paclitaxel as Second Line Treatment for Elderly Patients With Advanced Lung Cancer. UNC Lineberger Comprehensive Cancer Center. 2013.
BibTeX
@misc{anon2013LCCCPh, title = {LCCC 1210 - Phase II, Multicenter, Single Arm Study of the Tolerability of Weekly Nab-paclitaxel as Second Line Treatment for Elderly Patients With Advanced Lung Cancer}, author = {Anonymous}, journal = {UNC Lineberger Comprehensive Cancer Center}, year = {2013}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings